TechCrunch : Why SoftBank’s new $40B loan points to a 2026 OpenAI IPO

Why SoftBank’s new $40B loan points to a 2026 OpenAI IPO

SoftBank has taken on a new $40 billion loan to help it cover its $30 billion commitment to invest in OpenAI as part of the AI model maker’s record-breaking $110 billion raise last month, the Japanese conglomerate said on Friday.

Most striking is that the loan is unsecured and has a 12-month term, meaning it must be repaid or refinanced by next year. This could be a signal that the lenders believe OpenAI’s highly anticipated public listing will indeed come later this year, as some outlets, like CNBC, have reported. The loan is provided by JPMorgan Chase, Goldman Sachs, and four Japanese banks.

Since OpenAI’s IPO is bound to be one of the largest listings ever, if it does happen this year, that would presumably give SoftBank the liquidity to settle the debt in such a short time span. SoftBank’s new $30 billion investment in OpenAI brings its total bet on ChatGPT’s maker to over $60 billion.

TechCrunch : What will power the grid in 2035? The race is wide open

What will power the grid in 2035? The race is wide open

AI’s insatiable demand for power has tech companies hunting for new energy sources — a search that has fueled competition and investment into fusion and fission startups.

For many, natural gas is the easy answer for 24/7, baseload power. It’s tested, inexpensive, and widely available. But the war in the Middle East exposed its vulnerable supply chain after Iranian drone strikes took out a significant portion of natural gas infrastructure in Qatar, a major exporter. At the same time, surging demand has created a waitlist for gas turbines so long that today’s orders probably won’t be fulfilled until the early 2030s.

Those delays not only pose a risk to tech companies, but also to the natural gas industry itself.

In the U.S., 40% of the natural gas consumed today goes toward generating electricity. By the time the turbine shortages relent, the industry could be flush with a fresh crop of competitors. Both small modular nuclear reactor (SMR) startups and fusion power startups plan to start connecting their first commercial power plants to the grid in the next five to seven years, about how long it takes to get parts for a new natural gas power plant.

Nuclear threat
SMR startups might have the best shot at displacing natural gas power plants. In many instances, the technology tweaks the designs of existing fission reactors, but the fundamental physics has been proven and widely used for decades.

Several SMR companies aim to have reactors up and running before the decade is over. Kairos Power, which counts Google as a future customer, is one of them. The company received approval for its Hermes 2 demonstration reactor in 2024, and construction is well underway. Oklo, which merged with Sam Altman’s blank check company in 2024, is targeting 2028 for its first commercial operations, according to its annual report.

Others hope to follow a few years later. X-energy, which counts Amazon as an investor, is aiming for the early 2030s, while the Bill Gates-founded TerraPower, which has a deal with Meta, is planning to begin commercial operations in 2030.

To displace natural gas as the generating source of choice, SMRs will need to scale quickly, realizing the economies of scale that their business models depend on. That won’t be easy. But tech companies appear confident enough that they’re either investing in startups or signing agreements with them for gigawatts worth of power.

Fusion’s timeline
The other technology companies are warming to is fusion power. Though it isn’t as proven as fission, nuclear fusion promises to deliver large amounts of power using little more than seawater as fuel.

Fusion startups are also targeting the early 2030s — or sooner — to deploy their first reactors. Fusion power

One front-runner, Commonwealth Fusion Systems, is on track to flip the switch on its demonstration reactor next year. Its first commercial reactor, the 400-megawatt Arc, is expected to start generating power in Virginia in the early 2030s.

Another startup, a relative newcomer, hopes to start construction on a grid-scale power plant in 2030. Inertia Enterprises has based its technology on the reactor design employed by the National Ignition Facility, which was the first to prove that controlled nuclear fusion reactions could generate more power than they consume.

But Helion may have the most aggressive timeline out of all of them. The Sam Altman-backed startup is racing to build Orion, its first commercial-scale power plant, by 2028 to supply Microsoft with electricity. The company is also reportedly in talks with OpenAI to provide up to 5 gigawatts by 2030 and 50 gigawatts by 2035. To hit those numbers, Helion will have to build 800 reactors by the end of the decade and another 7,200 in the five years after that.

If the startup can deliver power in those quantities, it would completely rewrite the energy market. Last year, the U.S. added 63 gigawatts of new generating capacity across all sources. If Helion can build close to 10 gigawatts of new capacity every year, the company alone would add more power than the entire natural gas industry did last year.

The price problem
The challenge for all those companies — including gas turbine manufacturers — is cost.

SMR startups are counting on mass manufacturing to drive cost reductions, but that hypothesis has yet to be proven. Today, nuclear power is one of the most expensive forms of new generating capacity at around $170 per megawatt-hour, according to Lazard. Fusion faces a similar scale-up challenge, though it faces even more unknowns. Some experts predict one megawatt-hour from a fusion power plant could run about $150 initially.

New baseload natural gas power plants, meanwhile, run about $107 per megawatt-hour, per Lazard, though prices have been trending up in recent years, perhaps setting it on a collision course with both new fission and fusion reactors.

But they might all be undercut by renewables paired with batteries.
The costs of wind and solar power have dropped precipitously over the last decade. Wind power appears to have hit a bit of a plateau in recent years, but solar prices continue to inch downward with no signs of stopping. Batteries, too, have grown cheaper over the years, to the point where grids are installing massive quantities of them — 58 gigawatts-hours last year. Even without subsidies, solar paired with batteries ranges from $50 to $130 per megawatt-hour, overlapping fusion, fission, and natural gas.

Those figures are all with current battery technology derived from chemistries intended for electric vehicles. Newer designs aimed squarely at grid connections could slash prices further. Form Energy, for example, recently signed a deal to provide Google with electricity from a 30 gigawatt-hour iron-air battery. Another, XL Batteries, can repurpose old oil tanks to store its inexpensive organic fluid — the size of the battery is only limited by the size and number of the tanks.

Because those new batteries eschew the use of critical minerals like lithium, cobalt, or nickel, they promise to dramatically reduce the cost of long-duration energy storage to the point where it’s hard to make a case for anything else.

TechCrunch : Waymo’s skyrocketing ridership in one chart

Waymo’s skyrocketing ridership in one chart

Waymo is now providing 500,000 paid robotaxi rides every week across 10 U.S. cities, the company shared in a post on X this week. The eye-popping figure is reflective of the Alphabet-owned company’s accelerated commercial expansion. But it’s Waymo’s rate of growth in ridership and markets that offers a more compelling story.

In less than two years, the company’s average weekly paid robotaxi trips have grown tenfold, from 50,000 per week in May 2024 to 500,000 per week today. Over that same two-year timespan, Waymo has expanded within its initial markets of Phoenix, San Francisco, and Los Angeles — and beyond them to Austin, Atlanta, Miami, Dallas, Houston, San Antonio, and Orlando. Those seven cities in the Sun Belt were all added in just the past year.


Waymo’s robotaxi fleet has also grown, although the company has guarded those numbers and rarely provides updates. Data provided in December 2025 to the National Highway Traffic Safety Administration (NHTSA) shows the company had 3,067 robotaxis equipped with its 5th generation self-driving system. The company still uses that “over 3,000” fleet number today. That could soon change with the introduction of its 6th generation self-driving system, which will debut on the Zeekr minivan, known as Ojai, and the Hyundai Ioniq 5.

The rather steady 3,000-fleet figure, combined with growth in weekly paid rides, suggests that Waymo is squeezing more out of each robotaxi. That utilization figure is particularly important because empty Waymo vehicles roaming San Francisco or elsewhere don’t make money and increase congestion.

That growth does come with challenges. Waymo has received more scrutiny in recent months from the public and regulators. For instance, NHTSA and the National Transportation Safety Board are investigating the illegal behavior of Waymo robotaxis around school buses. Meanwhile, San Francisco city officials have raised concerns about how the company handles stuck robotaxis, including Waymo’s occasional use of police and firefighters to clear its vehicles.

Waymo’s ridership numbers are still a sliver of Uber’s human-driven ride-hailing business. Uber completed some 13.5 billion trips in 2025, a figure that includes completed ride-hailing and delivery trips, according to securities filings. The closest pure ride-hail number was shared during Uber’s August 2024 earning call when the company said it completed more than 1 million mobility trips per hour.

In other words, Waymo is not nipping at Uber’s tires just yet.

Still, with each month, the company’s lead in robotaxi rides grows wider.

A number of companies are vying for a slice of that robotaxi pie, although many have yet to offer a fully autonomous ride-hailing service that charges a fee. There are some Chinese robotaxi companies, including Pony.ai and WeRide, that charge for robotaxi rides, but none operate in the United States.

Tesla began operating a paid robotaxi service in Austin in January, and while CEO Elon Musk has said the company is near a fully autonomous ride-hailing service in California, it lacks any of the required permits to do so. Other companies, including Avride, Hyundai-owned Motional, and Zoox, are all pushing toward paid robotaxi services in various markets by the end of the year.

They all have some catching up to do.

The Information : Physical Intelligence Said to Discuss $11 Billion Valuation

Physical Intelligence Said to Discuss $11 Billion Valuation
Robotics startup Physical Intelligence is in talks to raise roughly $1 billion in a round that would value it at over $11 billion including the investment.

Robotics startup Physical Intelligence is in talks to raise roughly $1 billion in a round that would value the company at over $11 billion including the investment, according to a Bloomberg report Friday.

Founders Fund is participating in the round, and Lightspeed Venture Partners, Thrive Capital and Lux Capital are in talks to invest, the report said, though deal talks are early, and the terms and investors could change. If it closes, the investment would double the startup’s valuation; it last raised $600 million at a $5.6 billion valuation, including the investment, in November. Alphabet’s CapitalG led that round while existing investors Lux Capital, Thrive Capital and Jeff Bezos participated.

The company makes large artificial intelligence models to power robots. It was founded two years ago by former Google employees; professors from Stanford University and the University of California, Berkeley; and early Stripe employee and venture capitalist Lachy Groom.

FT Lex in depth: Will the AI data centre boom become a $9tn bust?

Lex in depth: Will the AI data centre boom become a $9tn bust?
The biggest groups splashing their cash may not make their money back, but will almost certainly live to tell the tale

Every so often, the human race comes down with building fever. Investors’ temperatures soar, lavish projections of demand go viral and spending swells. Once the fever breaks, there comes a long and painful convalescence.

Railways, early automobiles, telecoms networks, shale oil wells and Chinese apartments have all been through the cycle. Now it is the turn of data centres that host AI services. Can the multitrillion-dollar investment in these air-conditioned electronic warehouses — perhaps the biggest peacetime investment project in history — buck the historical trend of booms ending in busts? Some powerful people believe so, at least for them.

Among them are Meta Platforms boss Mark Zuckerberg, and his counterparts at Google parent Alphabet, Microsoft, Amazon and Oracle. The five are forecast to deploy $4tn of capital expenditure over five years, according to analyst estimates gathered by Visible Alpha, most of it on data centres they hope will reshape their businesses.


The spending is already reshaping their balance sheets. The formerly debt-light Google recently borrowed $32bn from the bond markets. Meta issued $30bn last November, and is also taking on off-balance-sheet commitments for massive data centre projects. If this proves just another case of investment delirium, there is much to lose.

Big tech, bigger ambitions
For all the hype, it is surprisingly hard to ascertain how many data centres are actually being built and at what cost. Researchers at McKinsey have crafted a figure of $5.2tn for AI-related computing facilities by 2030, based on 125 gigawatts at roughly $40bn per gigawatt. Data centres are measured by the power they require at peak times rather than the amount of data they crunch. For comparison, the UK’s peak electricity usage in 2025 was 46GW.

The McKinsey sum already looks light. A year ago, you could budget $25bn for chips and hardware, and $15bn on land, power and other inputs for a gigawatt of data centre power. Those numbers are now more like $35bn and $20bn, according to people familiar with data centre development. That takes the theoretical bill between now and 2030 to $6.9tn.

The McKinsey total may also not fully reflect the giant future investment by so-called “hyperscalers” such as Google, Meta and Amazon. Add the equivalent of half the $4tn analysts expect them to deploy and it ratchets up the number to a mountainous $9tn.

In real terms, that is roughly what China spent on residential real estate between 2016 and 2021, before its property market started to slump. And it is more than double the value of US investment in computing equipment in the five years preceding 2000s dotcom crash, according to data from the Federal Reserve Bank of St Louis.

The quest for profit
Assuming these colossal investments actually happen, it’s worth standing back to look at what returns would be required to make them earn their keep. One way is to take the minimum profit needed to match the rate of return, or cost of capital, that investors see as an acceptable minimum.

What is that rate, though? For infrastructure assets such as toll roads and power stations, the blended cost of debt and equity capital can be quite low, perhaps 7 or 8 per cent annually. Data centres are riskier than that. Professor Michael Roberts at the Wharton School at the University of Pennsylvania suggests an asset with cash flows correlated to the business cycle could require a return of 15 per cent or more.

Say, then, that an aggregate $9tn investment in data centres will require a 10 per cent return, or $900bn of profit per year after operators have accounted for expenses such as energy and depreciation. Assuming a profit margin of about one-third implies a need for $2.7tn of revenue. That is not far off what the US spent on software last year, according to official data.

For the hyperscalers, there are two places such revenue can come from: sales of products and tools they cook up in their AI labs, or renting their chips and servers to others. Microsoft does both. Amazon and Google do the latter. Meta, with no cloud business, has no direct revenue from data centres: everything it builds and commissions is for its own use.

Drill down, though, and business models get more fuzzy. Google and Meta say their internally generated AI models are souping up their ad sales businesses and keeping users hooked for longer. Microsoft charges for its AI-enhanced office tools but hopes to lure consumers and software programmers with free services too.

There are various ways to size up the revenue opportunity. Wells Fargo analysts posit, for example, that if internet advertising is growing by 15 per cent across the industry, Meta’s 25 per cent expansion suggests that roughly 10 percentage points of growth — or roughly $20bn in a year — is down to AI. Meta itself remains mum on its own assumed returns.

Investors’ faith, perhaps unsurprisingly, waxes and wanes. Meta shares plunged 11 per cent in October after it raised its capital expenditure forecasts, but rose 10 per cent in January when it did so again. Microsoft stock fell 10 per cent after its latest quarterly earnings, despite beating forecasts. What’s clear is that as cash gets funnelled into capital expenditure, there’s a lot less left in the near term for shareholders.


Executives are doing their best to project confidence, of course. Microsoft’s Satya Nadella argues AI should “bend the productivity curve”. OpenAI’s Sam Altman predicts the creation of “universal extreme wealth”. And Meta this month, in a gesture of supreme self-belief, issued top executives stock options exercisable only in the event that its shares soar, in some cases to six times their current price.

What if it all comes unstuck?
In the short term, such confidence looks justifiable. Between their own needs and those of customers, there is excess demand for all they can build and more. Those who rent out cloud capacity report dramatically escalating customer orders; Microsoft, Google and Amazon’s revenue backlog doubled last year, Goldman Sachs analysis shows.

That means that in the event of some kind of sudden reappraisal, hyperscalers can simply slow their rollout. This isn’t “if you build it, they will come”, unlike the telecoms-network boom and bust of the late 1990s, which left a glut of unused “dark fibre” that took a decade to find users.

But there’s no guarantee that what worked for last year’s investments will also work for next year’s, or that supply won’t start to outstrip demand. Zuckerberg admits he is spending to meet “the most optimistic cases”. Technology can change quickly, and with it, assumptions about how much capacity is needed and where. Nor is it clear how long expensive chips will last before they need to be replaced.

Another risk is simply that demand for AI products builds more slowly than expected. Around 95 per cent of AI projects in businesses currently fail, according to an oft-cited report last year by MIT. In the telecoms bubble, the fatal belief was that internet traffic was doubling every 90 days, whereas it was in fact doubling once a year. Timing matters enormously to financial returns — especially when there is debt to be serviced.


Some AI insiders are already warning of the risk that comes with grand projections. Dario Amodei, co-founder of Anthropic, has cautioned that if the real numbers go off course, big spenders could face bankruptcy as a result of “Yolo-ing” on capital expenditure, a reference to some of his peers’ you-only-live-once exuberance.

OpenAI might be the biggest wild card. Altman’s company, the inventor of ChatGPT, at one point wanted to commission 250GW of data centre capacity over time — potentially costing more than $10tn. Since OpenAI doesn’t hold data centres on its own balance sheet, that would have fallen to companies that specialise in building facilities for others such as CoreWeave and Crusoe, as well as chipmakers like Nvidia and Advanced Micro Devices.

Altman has subsequently moderated his plans. OpenAI had intended to spend $1.4tn of its own money on renting data centres over eight years; now it will spend $600bn over four. Altman is also discontinuing the company’s power-hungry video generator Sora, launched only a few months ago, in a sign that financial discipline may be becoming more of a focus. Lay-offs and bonus cuts at Meta tell a similar tale.

A much weirder variable may be OpenAI’s foundational “self-sacrifice” clause. Altman has committed to stop OpenAI’s march towards superhuman intelligence if a rival “comes close to” reaching that goal, and redirect its efforts to helping them out instead. What that means in practice is up for grabs. Investors in future data centres OpenAI might use will presumably hope it doesn’t happen.

Even without that, it’s hard to know exactly how much the hyperscalers themselves think they need. Meta gives guidance for its own investment plans but is separately agreeing to rent space from other cloud providers, which makes its potential consumption unclear. Given the fierce rivalry between AI model makers, the ambiguity is probably intentional.

If Zuckerberg’s plans change after he has invested a chunk of the $620bn analysts expect over the next four years, or if Meta agrees to leases it later realises it does not need, investors will not thank him for incinerating their capital. That said, since Zuckerberg controls his company through his super-voting shares, there’s not much investors can do besides grumble.

Even a massive climbdown would hardly be an existential issue for the Facebook owner, which last year made almost $200bn in advertising revenue. Google, Amazon and Microsoft too have real businesses to fall back on. OpenAI, in contrast, does not.

That, plus the fact that so much of their investment is funded out of cash flow, puts the more established Silicon Valley giants in a very different position to companies in previous manias, where massive outlays were financed by borrowings or equity issuance and the bursting of the bubble left participants with no business at all. Big Tech may not make its money back, but it will almost certainly live to tell the tale.

The AI countertrade
The tech giant that is conspicuously sitting out the data centre craze is Apple, which has retained an extremely lean balance sheet as its peers develop a taste for big debt issues and fixed assets.

While it has partnered with Google to power its own AI offerings, and dabbled unimpressively with “intelligence” features, the company behind the iPhone has eschewed the heavy lifting of developing models from scratch.

To see the difference, consider a somewhat old-fashioned but illustrative financial measurement known as “fixed asset turnover”. For each dollar’s worth of property and equipment on Apple’s balance sheet last year, it made more than $8 in revenue. That compares with $2 at Amazon and just over $1 at Meta. And at most of the hyperscalers this yield is declining rapidly.


For Apple boss Tim Cook, a lack of interest in covering the planet with servers is either a stroke of genius or a fatal miscalculation, something Carlyle’s head of strategy Jason Thomas likens to “a binary option”. If Apple were also to lose its grip over the device market — OpenAI, Google and Meta are all working on their own gadgets — it would be in serious trouble.

Another way of seeing this is that the iPhone maker can use its balance sheet for other things. Cook can choose his AI partners based on the best models available for a given task. Or he could do deals of an entirely different kind. Apple could, theoretically, buy Disney, creating a consumer media-and-tech juggernaut, with a little more than the $185bn Google has earmarked for capital expenditure this year.

Moreover, all that AI has to be used somewhere, and Apple still has an advantage when it comes to the computing devices on which hundreds of millions of users actually interact with large language models. That is not just phones: the launch late last year of OpenClaw, a customisable AI personal assistant that can run on a home computer, led to a rush of armchair tech buffs buying Apple’s dependable, user-friendly Mac Minis.

That speaks to another unknown that might work in Apple’s favour: the growing move towards “edge AI”, or models run on local devices. While Zuckerberg, Altman and peers drive towards godlike AI that sits in the cloud, many users may find their needs met by simpler models that reside on their laptop or phone, barely touching a data centre at all. If that’s the future, sitting out Big Tech’s generational spree could be a smart move.

FT : How long can Iran keep firing missiles?

How long can Iran keep firing missiles?
Five analysts assess Tehran’s capacity to sustain barrages against Israel and Gulf states

Night after night, the skies from Tel Aviv to Dubai erupt in sirens, streaks of light, flashes slowly blooming and fading in mid-air, and occasionally explosions on the ground.

As the missile war in the Middle East grinds on — with waves of US and Israeli air strikes on Iran met with daily retaliatory barrages — it has increasingly become a test of sustainability.

Iran’s early massive missile attacks have given way to a slower tempo of launches and smaller salvos since the US and Israel launched their war against the Islamic republic on February 28.

But it remains unclear how long Tehran can maintain the launch rates — and how long Israel and Gulf states can keep stopping the missiles with interceptors.

The FT asked five experts on Iran’s capabilities to assess how long the conflict could last.

Tom Karako, Center for Strategic and International Studies:

Iran’s ability to sustain its current level of drone and missile retaliation hinges largely on the effectiveness of US and Israeli strikes targeting its launch systems, infrastructure and command networks. Declining rates of missile launches suggest that these operations are disrupting Iran’s capabilities and forcing more cautious stockpile management.

While Tehran may be holding some advanced systems in reserve — as suggested by a reported intermediate-range ballistic missile launch towards the Diego Garcia military base in the Indian Ocean — doing so carries a “use it or lose it” risk. At the same time, Iran may be deliberately prolonging the conflict to impose political costs and pressure Washington into disengagement.

Although reduced launch rates imply a diminished ability to overwhelm defences, Iran probably retains the capacity to conduct complex, co-ordinated attacks. That could strain defences, particularly if interceptor stocks are depleted in key locations.

The extent of the surviving missile force, including those in underground facilities, remains uncertain. Nevertheless, Iran’s near-term ability to replenish its arsenal appears limited.

Danny Citrinowicz, Institute for National Security Studies:

Iran may lack the capacity for massive salvos, but its current approach appears to be a strategy designed to endure rather than overwhelm. This reflects long-term planning: Iran appears to be deliberately rationing its missile and drone use, recognising the conflict is likely to be prolonged. At the current tempo, it probably has enough missiles for several more weeks.  

Rather than relying on large-scale barrages, it is sustaining pressure through smaller but continuous attacks — limited missile strikes on Israel, waves of drones and frequent short-range missile launches towards Gulf states. 

Even a small number of strikes could hit critical energy and infrastructure targets. This poses a particular challenge for Gulf countries and gives Tehran disproportionate leverage.

Sascha Bruchmann, International Institute for Strategic Studies:

Iranian missile barrages are still largely subdued, especially when compared to the initial three days of the war. Interception rates remain very high. Iran used more cluster warheads against Israel. In some cases, these warheads split before intercept and the Israeli air defences did not engage every fragment. This results in numerous videos of munitions impacting, especially in densely populated areas of Tel Aviv, which can shape the perception that Iran is able to penetrate defences or land more hits. Each hit is amplified, celebrated and exaggerated.

Overall, interception rates remain high for the Gulf as well. Riyadh was targeted during a high-level political meeting but intercepted all missiles. The impression given by researchers on the ground is that very high interception rates continue. Successful missile attacks occurred this week but remain rare. In addition to a missile war, there is a propaganda war to influence target audiences in the Gulf and Washington.

Lynette Nusbacher, former intelligence adviser to the UK government:

The Iranians appear to be launching missiles as quickly as they can, within the constraints of concealment, moving, fuelling the liquid-fuelled munitions and pressing the launch button.

Every launch reveals a firing point location to American or Israeli target acquisition, and likely attracts an attack, and that, rather than inventory control, is what governs rates of fire.

There are credible estimates that the Iranians have 1,000 to 1,500 ballistic missiles in inventory, plus cruise missiles and drones, as well as a store of transporter-erector-launchers in reserve and fuel for their liquid-fuelled munitions. 

If they are able to continue launching from hardened shelters at their current reduced rate, they could easily keep going another week or two. If the Iranians used their less effective systems early in the current campaign, they’ll have longer range and more accurate missiles in inventory. 

Some of Iran’s more up-to-date missiles are solid fuelled, which makes them quicker to launch and more reliable. This could already be making each Iranian attack more potentially deadly.

Jim Lamson, James Martin Center for Nonproliferation Studies:

Iran’s ability to sustain its current level of retaliation remains highly uncertain, largely due to limited visibility into its remaining stockpiles.

While Tehran has recently deployed more advanced medium-range systems such as the Sejjil and Haj Ghasem, it has not yet used some newer or more sophisticated platforms, including the Fattah-2 hypersonic glide vehicle, suggesting certain capabilities may not yet be operational or are still being held in reserve — albeit likely in limited numbers. Similarly, additional short-range missile types could be introduced as the conflict continues.

However, Iran’s capacity to replenish its arsenal has been significantly degraded by US and Israeli strikes, which have damaged production facilities and critical supply chains for key components such as motors, propellants and guidance systems.

Although some short-term assembly may be possible using stockpiled parts, overall production capability appears severely constrained.

>>> PHARMA/BIOTECH M&A — THE STRUCTURAL BID BENEATH THE SELL-OFF (LC)

================================================================================
LAURENT CHEKROUN | 28 MARCH 2026 | INSTITUTIONAL NOTE
PHARMA/BIOTECH M&A — THE STRUCTURAL BID BENEATH THE SELL-OFF
================================================================================

CONTEXT: MARKETS SELLING OFF TODAY. USE IT.
The M&A bid in pharma/biotech does not follow the tape.
It follows patent expiry calendars — fixed, non-negotiable, arriving on schedule
regardless of what the Fed, tariffs, or Liberation Day 2.0 does to the XBI.

================================================================================
I. MARCH 2026: CONFIRMED DEALS
================================================================================

6 transactions / ~$17bn+ / 21 days / 4 continents / 0 macro catalysts

DATE ACQUIRER → TARGET VALUE AREA
------ ---------------------------------------- ----------- -----------------
6 Mar Servier → Day One Biopharma (BRAF) $2.5bn Rare Onco/Pediatric
20 Mar Novartis → Synnovation/Pikavation (PI3Ka) Up to $3bn Onco/Breast Ca.
25 Mar Merck → Terns Pharma (CML/TERN-701) $6.7bn Onco/Hematology
27 Mar Novartis → Excellergy (food allergy) Up to $2bn Immunology
Mar Gilead → Ouro Medicines (autoimmune) Up to $2.2bn Immunology
Mar Otsuka → Transcend (PTSD) Up to $1.2bn CNS/Psychiatry

Novartis: two deals in one week.
Servier: 68% premium to spot / 86% to 1M VWAP.
Otsuka (Japan): buyer universe is now global.

================================================================================
II. THE RUMOR BOARD — STATUS 28 MARCH 2026
================================================================================

▌HOT THIS WEEK — La Lettre / FT / WSJ active rumours

NBTX / NANO FP — Nanobiotix [La Lettre, 25 Mar]
Asset: NBTXR3 (JNJ-1900), radioenhancer nanoparticle. JNJ holds exclusive
licence and funds NANORAY-312 Ph3 (H&N cancer) since Mar 2025.
Rumour: La Lettre reported JNJ studying full takeover on 25 Mar.
Status: NBTX denied same day — "no intention, no process, factual
inaccuracies in report." Van Lanschot Kempen: "no indication of JNJ interest."
Read: JNJ already controls the asset operationally. A buyout just tidies the
cap table and eliminates future milestone payments. Unlikely pre-NANORAY data.
Mkt cap: ~€500m

RVMD US — Revolution Medicines [Jan 2026]
Asset: Daraxonrasib — RAS(ON) inhibitor, Ph3 pancreatic + NSCLC.
Rumour: MRK in talks at $28-32bn (FT Jan). Talks collapsed on price (WSJ).
AbbVie denied separately. MRK CEO Davis: "multi-tens of billions comfortable."
Status: No deal. Deal expected to re-emerge as Ph3 data matures.
Mkt cap: ~$23bn

ABVX / ABX FP — Abivax [Dec 2025 - Jan 2026]
Asset: Obefazimod — oral UC, Ph3 positive. +1,700% in 2025.
Rumour: La Lettre reported LLY prepared to pay €15bn ($17.5bn).
Status: CEO de Garidel dismissed formal talks Jan 20 ("noise"). French
Treasury review adds procedural complexity. Maintenance data Q2 2026 = key.
Stifel: "deal could happen ahead of readout."
Range: €12-20bn | Mkt cap: ~€8.4bn

▌STRUCTURAL CANDIDATES — analyst consensus M&A targets

VKTX US Viking Therapeutics VK2735 oral/sc GLP-1 ~$7bn NVO/AZN/PFE
GPCR US Structure Therapeutics Aleniglipron oral GLP-1 ~$4bn PFE/NVO/AZN
CELC US Celcuity Gedatolisib Ph3 PI3Ka ~$1.2bn NVS/PFE/AZN
TVTX US Travere Therapeutics Filspari FSGS Apr'26 ~$2.5bn CSL/REGN/AZN
IVA FP Inventiva Lanifibranor NASH Ph3 ~€500m AZN/GSK
MLIT US MapLight Pharma ML-007C-MA muscarinic ~$1bn BMS/ABBV/JNJ

================================================================================
III. THE FULL PICTURE
================================================================================

PATENT CLIFF — $200-300bn at risk by 2030
Keytruda (MRK) $29bn LOE 2028
Eliquis (BMS/PFE) $13bn LOE 2027-29
Darzalex (JNJ) $12bn LOE 2029
Stelara (JNJ) $10bn LOE 2025-26
Opdivo (BMS) $9bn LOE 2028
Current cliff = 2-4x the 2011-12 Lipitor era.
Internal R&D replaces ~1/3. The rest must be bought.
Big Pharma deal capacity: ~$1.3tn — most undeployed.

DEAL VELOCITY
2024: ~$55bn / ~35 deals (weakest since 2021)
2025: ~$133bn / 50 deals (+133% YoY — strongest since 2019)
2026E: $140-180bn / 50-60E (IQVIA / L.E.K. / McKinsey)

================================================================================
IV. WHY TODAY'S SELL-OFF IS THE POINT
================================================================================

When markets sell off:
> Acquirers' VWAP reference drops
> Premium paid on same asset shrinks
> Industrial urgency does not change
> Sellers with liquidity needs become more willing

April 2025: XBI -20% on Liberation Day tariffs.
M&A did not pause. Accelerated. XBI recovered +75% from low by December.

Merck/Terns (25 Mar): TERN-701's CML data does not care about the Fed.
The patent clock does not pause for risk-off.

RBC: the $400bn revenue gap is "far short" of being addressed by deals to date.
Premiums at 31-42% VWAP today will look cheap by 2027-28.

================================================================================
BOTTOM LINE
================================================================================

Six deals. Nine names on the rumor board. Three broken by La Lettre this week.
$1.3tn war chest mostly undeployed. Patent cliff with a fixed arrival date.

Markets are selling off. Biotech is red.
That is the opportunity. Use it.

================================================================================
Laurent Chekroun | 28 March 2026 | Confidential — Institutional Use Only
================================================================================

TechCrunch : Whoop has LeBron – now it wants your mom

Whoop has LeBron – now it wants your mom

For the better part of a decade, Whoop sold itself as a secret weapon for serious athletes. LeBron James was convinced to slap on the company’s fitness band in Whoop’s first year. Michael Phelps came soon after. Other Whoop wearers include Cristiano Ronaldo, Patrick Mahomes, and Rory McIlroy. The message to the public? The world’s best performers track their bodies with this device, and you can, too.

It has worked. Whoop, the Boston-based health wearable company that Will Ahmed founded in his senior year at Harvard, now operates in more than 200 countries, and, according to Ahmed, grew revenue more than 100% last year, as well as reached cash-flow positive. The hardware — a band worn around the wrist, bicep, or torso — measures sleep, recovery, heart rate variability, and a growing list of biomarkers. The subscription model, which bundles hardware and software for between $200 and $360 a year — the device itself included, with no separate purchase required— has proven remarkably sticky: 83% of monthly active users open the app on any given day, a ratio that Ahmed says trails only WhatsApp.

The next chapter is a harder sell.

Ahmed, 36, wants Whoop to be less of a performance tool and more of a life-saving one — a continuous health monitor that doesn’t just help you recover from a hard workout, but one day tells you, unprompted, that you’re about to have a heart attack and need to get to a hospital.

The company has already launched medically cleared features including ECG monitoring and atrial fibrillation detection — a capability that flags an irregular heartbeat that can lead to stroke — and what it calls blood pressure “insights,” which Ahmed says makes Whoop the first wearable to offer the feature.

The FDA challenged that last one in a warning letter last summer, arguing the feature constituted medical diagnosis rather than wellness monitoring; Whoop said the FDA was “overstepping its authority,” and kept building.

Today, a blood testing partnership with Quest Diagnostics — which has over 2,000 U.S. locations — lets members take a blood test and upload their biomarkers directly into the app, where a clinician reviews the results alongside their Whoop data. A feature called Health Span calculates your biological age. Ahmed says it has become the company’s most popular feature since its launch in May of last year.

The device itself has no screen, no notifications, no step counter. The decision was strategic from the start. “If you have a screen, then you’re a watch,” he tells TechCrunch via a Zoom call. “And if you’re a watch, then you’re competing with a lot of other watches, because people will never wear two watches.”

Not only can Whoop be worn alongside whatever watch you already own, he suggests, it can be tucked away entirely, a sensor slipped into a bicep sleeve, a sports bra, or a pair of shorts, disappearing into your clothing. It’s probably safe to say the overwhelming majority of Whoop’s customers want to wear the band as a fashion statement, but when asked directly, Ahmed offers that the company’s apparel line, launched in 2021, grew 70% last year.

But Whoop isn’t alone in moving beyond its roots to wanting to pull everyone into the tent. Oura, the Finnish company behind the smart ring that has become Whoop’s most direct rival, has built a large and loyal following of its own — largely among the kind of high-performing professionals who approach their bodies with the same rigor they bring to their work.

Oura’s model works differently. Customers buy the ring outright for around $350, then pay roughly $70 a year to access the platform. When I spoke with Oura chief product officer Dorothy Kilroy last fall, she said retention at the 12-month mark was hitting the high 80s, a remarkable figure for any wearable, most of which quickly wind up in a drawer.

Both companies now say women are their fastest-growing segment, and last fall they announced blood-testing partnerships within one day of each other — a coincidence that neither side was eager to discuss.

Whoop’s numbers still reflect where it started. Though Ahmed is circumspect about sharing too many figures publicly, he says Whoop skews more male than female. He also says the business is now roughly evenly split between the U.S. and the rest of the world — a shift from just a few years ago. Whoop formally ships to 60 countries.

What has set Whoop apart, at least in its telling, is that its most famous users didn’t have to be persuaded. The Australian Open earlier this year instructed players including Carlos Alcaraz to remove their Whoop bands mid-tournament, despite the device having been approved by the International Tennis Federation. The players pushed back. Though Whoop has brand ambassadors — Aryna Sabalenka is one — others like Alcaraz and Jannik Sinner, both of whom wear Whoops under their wristbands, simply didn’t want to take them off.

“It created a whole set of media outrage,” Ahmed says a little gleefully of the resulting coverage, “and further spotlighted the fact that all these very talented people are just organically wearing Whoop because of the value it provides.”

Ahmed is careful to protect it. The company has a long-standing policy against giving athletes equity in exchange for wearing the band. His reasoning? If they like the product, they’ll wear it regardless. Formal partnerships with Ferrari, the PGA Tour, and UCI mountain biking work differently; they’re about putting the brand in front of larger audiences who share the same sensibility.

Oura, by the way, is doing the same math. Founded just one year after Whoop, the company is widely reported to be exploring an IPO. If Oura goes public first, it sets the financial benchmarks — revenue multiples, growth rates, retention metrics — against which Whoop will be measured. Whoop currently employs around 750 people and is in the middle of hiring 600 more.

Ahmed gives little away on the subject. “If we focus on building great technology and growing our business,” he says, “we’re going to be happy with Whoop when we’re a public company, independent from who goes public first.”

He speaks throughout the conversation the way someone does when they’ve thought carefully about what they should and shouldn’t say. Ahmed was captain of the Harvard squash team and counts Ali Farag, who went on to become world number one, among his former teammates — though he’s quick to note that proximity to greatness shouldn’t be mistaken for greatness itself.

“You probably have the wrong impression of how good I am at squash on the basis of me being teammates with him,” he jokes.

He started building what would become Whoop in 2011, reading hundreds of medical papers while studying economics and government, trying to solve a problem he’d experienced firsthand: overtraining without any reliable way to measure its toll on his body.

Whoop isn’t just Ahmed’s first company. It has been his only full-time job. When I ask whether he’d recommend that path to a founder sitting where he was in 2012, it’s the question he answers most freely.

Starting a company is, for the right person with the right intentions, “without question, the most extraordinary thing you can do in your career.” But it is, he adds, “a very painful experience to be an entrepreneur and to try to build something from scratch, and you have to have a reasonably high pain threshold that I think often gets lost in the glamour of fundraising announcements and milestones.” You need to be, he says, “more obsessed with the problem you’re solving than with the idea of being a founder.”

He doesn’t seem to have much doubt about which side of that line he’s on.